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Abstract
Epidemiological and genetic studies have identified elevated levels of lipoprotein (a) ((Lp(a)) as a causal and
independent risk factor for cardiovascular diseases (CVD). The Lp(a)-induced increased risk of CVD may be mediated
by both its proatherogenic and prothrombotic mechanisms. Several guidelines recommend screening of Lp(a) level;
however, there are few treatment options for the management of patients with elevated Lp(a). Several
new medications for Lp(a) are under development. PCSK9 inhibitors, apolipoprotein (a)-antisense, and
apolipoprotein(B-100)-antisense mipomersen have shown promising results. Lp(a) reduction will continue to
be an active area of investigation.
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Background
Most clinical trials research investigating the effects of
cholesterol lowering medications on the prevention of
cardiovascular disease (CVD) have focused on low dens-
ity lipoprotein cholesterol (LDL-C). Elevated serum level
of lipoprotein (a) (Lp(a)), an LDL particle linked to the
plasminogen-like glycoprotein, has been an independent
risk factor for atherosclerotic CVD, particularly in those
with high low-density lipoprotein cholesterol (LDL-C) or
non- high-density lipoprotein cholesterol (HDL-C) [1, 2].
Effects of Lp(a) on vasculature are not fully understood.
Human and animal studies have shown that Lp(a) can
enter intima of arteries [3]. Thus, it may have a role in in-
flammation of intima, thrombosis, and foam cell forma-
tion; all these processes are involved in development of
atherosclerosis [4, 5]. It is estimated that around 1.5 billion
people have Lp(a) levels greater than 500 mg/L [6]. Lp(a)
levels are, to a large extent genetically determined, stable
are not significantly influenced by diet, exercise, or other
environmental factors [6].
This review article addresses the structure, genetics,
and function of Lp(a) as well as indications for screening
and therapy.
Lp(a) structure
The Lp(a) structure is similar to that of LDL, in which a
glycoprotein, apolipoprotein(a) [apo(a)], is covalently
bound to apolipoprotein B (apoB) by a disulfide bridge,
in a 1:1 molar ratio [2]. Cholesterol content of Lp(a) as
well as its density are similar to those of LDL particles.
Its structure is similar to plasminogen, including a com-
mon gene sequence [2]. The apo(a) chain contains five
domains or kringles; the fourth kringle has a homology
with the fibrin-binding domain of plasminogen which
causes Lp(a) interference with fibrinolysis. In addition,
Lp(a) promotes foam cell formation and cholesterol
deposition in atherosclerotic plaques by binding to
macrophages [7].
Lp(a) genetics and serum concentration
Serum levels of Lp(a) are mostly genetically determined.
The polymorphism in apo(a) gene [LPA] results in the
heterogeneity in its size and molecular weight [1, 2].
Lp(a) show high ethnic variability. Atherosclerosis Risk
in Communities (ARIC) study has shown that median
Lp(a) levels are three times higher in African-Americansas
compared to the Caucasions [8]. Matthews et al. [9] also
reported higher levels of Lp(a) in African-American com-
pared to Caucasians.
Distribution of Lp(a) concentrations is highly skewed par-
ticularly toward extremely high levels [2, 7, 10]. Lp(a) levels
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range between 20 to more than 2000 mg/L with almost
20 % of individuals at the extreme levels [2, 7, 10].
There is a heterogeneity in size of Lp(a), ranging from
187 to 662 KDa, it depends on the number of Kringle of
IV type 2 repeats in the Lp(a) gene [11]. There is a
strong inverse relationship between the size of Lp(a) and
its serum levels with smaller size correlating with higher
serum levels [2]. Also smaller Lp(a) is associated with in-
creased risks of cardiovascular disease (CVD). Due to its
strong genetic determination, Lp(a) levels are stable and
are not significantly influenced by gender, age, or envir-
onmental factors [7, 10].
Lp(a) measurement
Originally Lp(a) was detected by gel electrophoresis as a
“sinking pre-beta lipoprotein” band [2]. There are issues
regarding Lp(a) measurement and standardization which
have complicated Lp(a) level interpretations in the con-
text of CVD risk. There are several diferent methods of
reporting Lp(a) leves that may confuse physicians. Some
laboratories report Lp(a) mass, while others report it as
Lp(a) concentration, or Lp(a) protein. Efforts has been
made in standardization on measurement and reporting
the Lp(a) levels. Several assays for measurement of Lp(a)
are available, such as enzyme-linked immunosorbent as-
says (ELISAs), non-competitive ELISA, immunonephelo-
metry, immunoturbidometry, and latex immunoassays
[11–13]. The European Atherosclerosis Society guide-
lines [12] recommended use of method which is robust,
accurate, economically priced with coefficient of varia-
tions (CV) <10 %. Also they have recommended that
antibodies which are used in assay kits should be apo(a)
isoform-insensitive in which Lp(a) is measured inde-
pendently of Lp(a) size and number of kringle-IV re-
peats. Immunoassays, protocols for blood collection,
plasma/serum isolation should be standardized for qual-
ity control. A secondary reference Lp(a) preparation at
an international level approved organizations such as
International Federation of Clinical Chemistry and the
World Health Organization. Manufactures making assays
for measurement of Lp(a) should seek to minimize the ef-
fects of apo(a) size on Lp(a) levels and use isoform-
insensitive polyclonal antibodies (anti-apo(a) capture and
anti-apo(B) [11–15].
Denka-Seiken immunoturbidimetric assay (Atherotech
Diagnostics Lab; Berkeley Extended-Range Lp(a) Test) is
a high-duality and validated assay that measures Lp(a)
mass with CV <3 %.
Lp(a) and cardiovascular disease (CVD)
Serum levels of Lp(a) are an independent risk factors for
CVD. Several studies have indicated that the risk is
markedly elevated at the extreme Lp(a) levels [16, 17].
For example, the Copenhagen Heart Study showed that
patients with Lp(a) levels above 500 mg/L have 2–3 fold
increase in the risk of myocardial infarction. A large
Mendelian randomized study as well as the EPIC-
Norfolk, and Brunek cohort studies demonstrated that
patients with high Lp(a) levels have two-fold increase in
CVD [7]. Recently Willeit et al. suggested that Lp(a)
measurement, particularly in intermediate risk category
of patient (as determined by Framingham risk score)
predicts CVD outcomes and improves CVD risk predic-
tion [18].
HIgh levels of Lp(a) are commonly detected in pa-
tients with premature coronary heart disease (CHD).
Genest have reported elevated Lp(a) levels in 18.6 % of
patients with premature CHD with 12.7 % of them having
no dyslipidemia [19]. The National Cholesterol Education
Program for the Detection, Evaluation and treatment of
hypercholesteremia in adult (NCEP-ATP III) states that
Lp(a) levels are predictor of CV risks with higher levels as-
sociated with greater risk of having an CV events [20].
The Emerging Risk Factors Collaboration have found that
each 3.5-fold increase in Lp(a) resulted in a 13 % increase
in CVD risk [21]. They also found that this association
was continuous and become proportionally more import-
ant with higher Lp(a) levels. Moreover, they found that
this association still persist even after correction for other
lipid parameters.
Size of Lp(a) also modulates CHD risk with the smaller
apo(a) isoforms associated more strongly with the risk of
CHD compared to larger isoforms [21]. Genome-wide as-
sociation studies (GWAS), Mendelian randomization, and
epidemiologic studies revealed a link between LPA geno-
type with high Lp(a) levels and adverse CV events [6]. In a
systemic review of 40 studies involving 58,000 partici-
pants, Erqou et al. have shown that people with smaller
apo(a) isoforms have approximately 2-fold higher risk of
CHD or ischemic stroke than those with larger isoforms
[21]. Interestingly, they found that after adjustment for
cholesterol and other CVD risk factors, the association
was only slightly attenuated, strengthening the concept
that Lp(a) is an independent risk factor for CHD. Likewise,
European Prospective Investigation of Cancer cohort have
observed that after adjustment for LDL-C, there is an as-
sociation between Lp(a) levels and CVD [7]. Recently,
Khera et al. analysed a subgroup of white participants
of the JUPITOR study and showed that in statin-
treated patients with very low level of LDL-C, elevated
Lp(a) levels represent a significant determinant of re-
sidual risk for CVD [22].
LPA gene polymorphism influences Lp(a) levels and
the risk of myocardial infarction with some common
variants of LPA gene associated with more than 50 %
risk of heart diseases [1, 2]. Two gene association studies
have suggested a causative relationships between ele-
vated levels of Lp(a) and increased risk of CVD events.
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The 10 years Framingham cardiovascular risk score does
not include Lp(a) levels. However, including it may im-
prove risk assessment. To support this idea, several cohort
of patients (both Caucasian and African-American pa-
tients) were used to develop 2013 American College of
Cardiology/American Heart Association (ACC/AHA) car-
diovascular risk calculator [20]. This model incorporated
same parameters as the 2008 Framingham cardiovascular
risk score except that it included only hard endpoints
(both fatal and not fatal myocardial infarction and stroke).
Thus, this calculator may be used in some populations;
while it is not accurate in others (Rotterdam) [23, 24].
In addition, elevated levels of Lp(a) are associated with
stroke, which is more common in men than women. El-
evated Lp(a) in patients with essential hypertension
seems to play a role in the development of target-organ
damage. In one study, Sechi et al. have shown that re-
gardless of blood pressure, Lp(a) levels were the best
predictor of target-organ damage involving arterial wall,
heart, and kidney [25].
Lp(a) may also play a role in plaque rupture and cor-
onary thrombosis[23–26]. In patients with acute cor-
onary syndrome, Lp(a) levels are predictive of risk of
cardiac death.
Screening
Recommendations for Lp(a) screening are not standard-
ized among atherosclerosis, lipid, and CV prevention so-
cieties. The 2013 ACC/AHA treatment guideline did not
examine Lp(a) role and thus did not recommend Lp(a)
screening [26]. However, both the National Lipid Associ-
ation (NLA) and the European Atherosclerosis Society
Consensus Panel recommended Lp(a) measurement for
patients with familial hypercholesteremia, strong family
history of CVD and/or elevated Lp(a), personal history
of premature CVD, recurrent CVD despite statin treat-
ment, inadequate response to statins, and ≥ 3 % 10-year
risk of fatal CVD according to the European guideline,
and ≥ 10 % 10-year risk of fatal or non-fatal CHD ac-
cording to the US guidelines [12, 27]. The 2012 Canadian
Cardiovascular Society recommend considering secondary
testing, including Lp(a) measurement, in a moderate risk
patients [28]. They emphasize that LDL-C reduction is the
primary target in management of dyslipidemia.
Cardiovascular risk in patients with elevated Lp(a)
There is no definite clinical trial investigating effect of
lowering Lp(a) on prevention of CHD; thus, all recom-
mendations for the treatment are speculative. Thus
ACC/AHA guidelines does not identify Lp(a) as the pri-
mary target for lipid-lowering therapy [26]. The European
Atherosclerosis Society Consensus Panel (EASCP) sug-
gested that Lp(a) level below 500 mg/L are desirable [12].
The primary goal of treatment of elevated Lp(a) is to
lower LDL-C to the patient’s target LDL-C level based on
patient’s risk category. For reduction in CHD, EASCP con-
siders assessing and possibly treating Lp(a) as a priority
after lowering LDL-C. Studies suggest that risk of CVD-
associated elevated Lp(a) levels is much higher in the pres-
ence of other CV risk factors including high LDL-C levels
[29]. Several studies showed that lowering LDL-C in the
presence of high Lp(a) resulted in a reduction in CVD
events [30]. Thus, statins should be considered as a first-
line therapy for the treatment of elevated LDL-C and
Lp(a). Interestingly some studies recommend more ag-
gressive treatment of LDL-C in the presence of high Lp(a)
[2]; the effectiveness of this approach has not been fully
studied. It should be noted that there is ongoing contro-
versy about specific cholesterol targets. In patients
with elevation of Lp(a) without an indication for
LDL-C therapy, beneficial effect of statin for risk re-
duction is not clear.
Clinical studies investigating the effect of lowering
Lp(a) and CHD risks seem to lack consistency in regards
to patient selection, drugs used, and the method for
Lp(a) measurement. LDL-C levels are frequently calcu-
lated using Friedwald equation which includes Lp(a).
Using Dahlen equation, we and others have shown that
in patients with high levels of Lp(a) this equation overes-
timates LDL-C [31, 32]. In patients with extreme Lp(a)
levels this overestimation is high (up to 40 %) [32]. Thus,
in a patient with very high Lp(a) level, if LDL-C is driven
lower pharmacologically, a larger proportion of calcu-
lated LDL-C is actually contributed by Lp(a). The recent
IMPROVE-IT study proposed that lowering LDL-C level
to 1.3 mmol/L is associated with lower repeated CV
events compared to the higher levels [33]. However, it is
important to estimate the true levels of LDL-C in this
study and its relationship with CV events.
Treatment
Different classes of lipid-lowering medications have dis-
tinct effects on LDL and Lp(a). Statins and bile acid se-
questrates reduce LDL-C, but lower Lp(a) only slightly.
In patients with the familial hypercholesteremia statins
decrease Lp(a) by 17–22 % [34]. Some studies showed
that statins may raise Lp (a) mass by 10–50 % [6]. Fibric
acid derivatives do not decrease Lp(a) except for bezafi-
brate which lowered Lp(a) by 39 % [35]. Bezafibrate is
not approved for use in North America.
High dose of nicotinic acid (2–4 g/day) is the most ef-
fective agent that lowers Lp(a) by up to 40 % [1, 2]. Per-
centage lowering appears to be greater at extreme Lp(a)
levels. It also has other beneficial effects including re-
duction of LDL-C, apoB, small LDL-C, and triglycerides,
and raises HDL-C. However, no study has correlated
nicotinic acid-induced reduction in Lp(a) with CVD out-
comes. In Post hoc analysis of the AIM-HIGH trial,
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Albers et al. have suggested that despite the fact that
niacin induced favorable changes in lipid profile; it did
not improved CV risk [36]. They suggested that in pa-
tients with elevated Lp(a) statins remain the basis of
treatment with the target of reducing LDL-C below
1.8 mmol/L. But this notion has not been studied in pa-
tients with extreme Lp(a) levels. The subsequent study,
HSP-2-THRIVE study also failed to show a significant
benefit in reducing major vascular events with nicotinic
acid despite reduction in Lp(a) levels [37]. Also, the Na-
tional Cholesterol Education Program Adult Treatment
Panel III stated that the clinical utility of niacin is not
fully established due to the fact that the frequency of ex-
tremely high Lp(a) level is low [20]. Interestingly, in a
case report of a patient with normal lipid profile but ex-
tremely elevated Lp(a) who developed a non-ST elevation
myocardial infarction, we have shown that treatment with
a combination of nicotinic acid and statin may be benefi-
cial in reducing further CHD events [38]. It is unclear if
nicotinic acid has a role in reduction of CVD events.
However, a recent meta-analysis suggests that nicotinic
acid is useful for CV event reduction [39]. In patients with
elevated Lp(a), EASCS recommends treatment with nico-
tinic acid 1–3 g/d in high risk patients to achieve Lp(a)
levels below 500 mg/L as a secondary goal after reduction
of LDL-C [12].
There are also several recent pharmacologic develop-
ments pertinent to lowering Lp(a). One is mipomersen,
an apoB antisense oligonucleotide that inhibits synthesis
of apoB. This drug has been approved by FDA for lower-
ing LDL-C, apoB, TC, and non-HDL-C in patients with
homozygous familial hypercholesteremia [1, 2, 40]. A
meta-analysis investigating the effect of this agent on
Lp(a) levels have found a reduction of 26 % in Lp(a)
from baseline [1]. Due to its hepatotoxicity, this agent
can only be prescribed by specially certified physicians.
Another development is human monoclonal antibody
to Proprotein convertase subtilisin/kexin9 (PCSK9)
[1, 2, 40]. PCSK9 is a protein which binds to LDL-
receptor (LDL-R). This complex is subject to proteolytic
degradation, thus preventing recycling of LDL-R to the
cell surface and impairing the clearance of plasma LDL-C.
The PROFICIO (Program to Reduce LDL and CV Out-
comes Following Inhibition of PCSK9 In Different Popula-
tions) has shown that administration of Evolocumab, a
PCSK9 inhibitor resulted in significant dose-dependent
decrease in Lp(a) by up to 29.5 % and LDL-C by 52 %
[41]. Alirocumab, another monoclonal antibody, showed
similar results as evolocumab in terms of Lp(a) reduction
[1, 40]. In a meta-analysis of 20 randomized controlled tri-
als, Li et al. demonstrated that treatment with PCSK9 in-
hibitor resulted in reduction in Lp(a) as well as other lipid
parameters such as LDL-C, TC, triglycerides, and apoB.
Even though PCSK9 inhibitors reduce Lp(a), their effect
on CVD outcome remains unclear [1, 40]. Also, it is un-
clear where PCSK9 inhibition fits into current thera-
peutic guidelines and whether this agent will be used to
specifically lower Lp(a) in addition to the robust LDL-C
reduction.
Lomitapide, and microsomal triglyceride transfer pro-
tein (MTP) inhibitor, approved by FDA as an adjunct to
diet and lipid lowering therapy lowers LDL-C, TC, apoB,
and non-HDL-C in patients with homozygous FH [42].
MTP transfers lipids to apoB in hepatocytes and entero-
cytes. MTP inhibition impair VLDL formation. In phase
II clinical trial this agent has been shown to lower Lp(a)
by 17 % [40]. There is concern about its hepatotoxicity,
thus, it should be prescribed by specifically certified phy-
sicians. The long-term effect of this agent on Lp(a) re-
duction needs to be determined.
Inhibitors of cholesterol ester transfer protein (CETP),
a plasma protein that transfers cholesterol esters from
HDL to apoB-containing particles raise HDL-C levels
[40]. While the first trials of these inhibitors, torcetrapib
and dalcetrapib were terminated due to side effects,
newer agents anacetrapib and evacetrapib showed bene-
ficial lipid effects without serious side effects. In the DE-
FINE trial, anacetrapib resulted in HDL-C elevation of
138 % and lowering of LDL-C and Lp(a) by 40 and 36 %,
respectively [43]. The effect of this agent on lowering
CVD is under investigation.
Recently both animal and human studies have shown
that specifically targeting Lp(a) with second generation
antisense oligonucleotides lowers plasma level of Lp(a)
by inhibiting apo(a) mRNA translation and thereby syn-
thesis [44]. In a randomized, double-blind, placebo-
controlled phase I study, Tsimikas et al. [45] have shown
that treatment of volunteers with second generation
antisense oligonucleotides that inhibits Lp(a) mRNA
translation reduces Lp(a) levels and oxidized phospho-
lipid associated with apo(B) levels, in a dose dependent
manner, up to 89 and 93 %, respectively. They also
showed this drug is safe and tolerable. It is a potent and
selective in reducing Lp(a) levels, thus, it could be used
as a potential therapeutic drug to reduce CVD events
and progression.
Lipoprotein apheresis, an extracorporeal therapy, is
the most effective way to lower Lp(a) [1, 2, 40]. Several
studies have shown its lowering effect on serum lipids
and Lp(a) as well as its safety [1, 40]. Currently, most
lipid societies recommend apheresis mainly for patients
with familial hypercholesteremia [40, 46]. The German
Committee of Physicians and Health Insurance Funds
and England’s HEART-UK recommend apheresis for
patients with Lp(a) > 600 mg/L with progressive CHD
[46, 47]. Both longitudinal cohort study and prospect-
ive observational study of patients with CHD and ele-
vated Lp(a) levels showed that lipoprotein apheresis
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resulted in Lp(a) level reduction of more than 60 %
after each apheresis session as well as lowering major
adverse coronary events rate per patient by almost
80 % [40]. In a randomized controlled interventional
study on patients receiving weekly lipoprotein apher-
esis, Safarova et al. demonstrated that lipoprotein
apheresis resulted in Lp(a) level reduction by 73 ± 12 %
[48]. Also, coronary angiography showed a reduction
in median percent diameter stenosis by 2.0 compared
to the group receiving only atorvastatin. Julius et al.
demonstrated that lipoprotein apheresis resulted in re-
duction of CV events more significantly in patients
with elevated Lp(a) levels compared to patients with el-
evated LDL-C levels [49]. Given that apheresis removes
both Lp(a) and LDL-C, the therapeutic effects of
apheresis seen in above studies is likely related to re-
duction in these particles. A major limitation of apher-
esis is that both Lp(a) and LDL-C levels, particularly
Lp(a) levels, rebound to baseline levels within 2 weeks
of treatment [40]. Other limitations include its cost
and limited access.
Future studies
Lp(a) is considered as an risk factor for CVD. In order
to be used for risk stratification and as a major cardio-
vascular risk factor, further studies should be conducted
to show Lp(a) predictive power for CVD and beneficial
effects of its lowering.
Conclusions
Epidemiologic and genetic studies provide evidence that
Lp(a) is an independent, causal risk factor for CVD. Ele-
vated Lp(a) levels promote atherosclerosis and throm-
bosis. Screening and treatment of selected patients are
recommended. Diet, exercise, and lifestyle modification
have no effect on Lp(a). Niacin and lipoprotein apheresis
are the most effective ways currently available to lower
Lp(a). Recent pharmaceutical developments show prom-
ising results on reduction in Lp(a) levels, but there is no
study investigating their effect on CV events. Thus, large
prospective randomized-controlled trials are needed to
investigate relationship between lowering Lp(a) and re-
duction in CVD.
Competing interest
The authors declare that they have no competing interests.
Authors’ contribution
RS wrote the first draft of the manuscript and JF edited it. Both authors read
and approved the final manuscript.
Acknowledgement
N/A
Received: 29 July 2015 Accepted: 10 March 2016
References
1. Kassner U, Schlabs T, Rosada A. Lipoprotein(a)-An independent causal risk
factor for cardiovascular disease and current therapeutic options.
Atheroscler Suppl. 2015;18:263–7.
2. Jacobson TA. Lipoprotein(a). Cardiovascular Disease, and Contemporary
Management. Mayo Clin Proc. 2013;88(11):1294–311.
3. Nielsen LB, Grønholdt ML, Schroeder TV, et al. In vivo transfer of
lipoprotein(a) into human atherosclerotic carotid arterial intima. Arterioscler
Thromb Vasc Biol. 1997;17(5):905–11.
4. Erqou S, Kaptoge S, Perry PL, et al. Emerging Risk Factors Collaboration, et
al. Lipoprotein(a) concentration and the risk of coronary heart disease,
stroke, and nonvascular mortality. JAMA. 2009;302(4):412–23.
5. Boffa MB, Marcovina SM, Koschinsky ML. Lipoprotein(a) as a risk factor for
atherosclerosis and thrombosis: mechanistic insights from animal models.
Clin Biochem. 2004;37(5):333–43.
6. Yeang C, Witztum JL, Tsimikas S. 'LDL-C' = LDL-C + Lp(a)-C: implications of
achieved ultra-low LDL-C levels in the proprotein convertase subtilisin/kexin
type 9 era of potent LDL-C lowering. Curr Opin Lipidol. 2015;26(3):169–78.
7. Dubé JB, Boffa MB, Hegele RA, et al. Lipoprotein(a): more interesting than
ever after 50 years. Curr Opin Lipidol. 2012;23(2):133–40.
8. Ohira T, Schreiner PJ, Morrisett JD, et al. Lipoprotein(a) and incident
ischemic stroke: the Atherosclerosis Risk in Communities (ARIC) study.
Stroke. 2006;37(6):1407–12.
9. Matthews KA, Sowers MF, Derby CA, et al. Ethnic differences in
cardiovascular risk factor burden among middle-aged women: Study
of Women's Health Across the Nation (SWAN). Am Heart J.
2005;149(6):1066–73.
10. Lippi G, Guidi G. Lipoprotein(a): an emerging cardiovascular risk factor. Crit
Rev Clin Lab Sci. 2003;40:1–42.
11. Marcovina SM, Albers JJ, Scanu AM, et al. Use of a reference material
proposed by the International Federation of Clinical Chemistry and
Laboratory Medicine to evaluate analytical methods for the determination
of plasma lipoprotein(a). Clin Chem. 2000;46(12):1956–67.
12. Nordestgaard BG, Chapman MJ, Ray K, et al. Lipoprotein(a) as a
cardiovascular risk factor: current status. Eur Heart J. 2010;31(23):2844–53.
13. Marcovina SM, Koschinsky ML, Albers JJ, et al. Report of the National
Heart, Lung, and Blood Institute Workshop on Lipoprotein(a) and
Cardiovascular Disease: recent advances and future directions. Clin Chem.
2003;49(11):1785–96.
14. von Eckardstein A, Schulte H, Cullen P, et al. Lipoprotein(a) further increases
the risk of coronary events in men with high global cardiovascular risk. J
Am Coll Cardiol. 2001;37(2):434–9.
15. Rouy D, Grailhe P, Nigon F, et al. Lipoprotein(a) impairs generation of
plasmin by fibrin-bound tissue-type plasminogen activator. In vitro studies
in a plasma milieu. Arterioscler Thromb. 1991;11:629–38.
16. Kamstrup PR, Tybjærg-Hansen A, Nordestgaard BG. Extreme lipoprotein(a)
levels and improved cardiovascular risk prediction. J Am Coll Cardiol. 2013;
61(11):1146–56.
17. Kamstrup PR, Benn M, Tybjærg-Hansen A, et al. Extreme lipoprotein(a) levels
and risk of myocardial infarction in the general population: the
Copenhagen City Heart Study. Circulation. 2008;117:176–84.
18. Willeit P, Kiechl S, Kronenberg F, et al. Discrimination and net reclassification
of cardiovascular risk with lipoprotein(a): prospective 15-year outcomes in
the Bruneck Study. J Am Coll Cardiol. 2014;64(9):851–60.
19. Genest J. Lipoprotein disorders and cardiovascular risk. J Inherit Metab Dis.
2003;26(2–3):267–87.
20. National Cholesterol Education Program (NCEP) Expert Panel on Detection,
Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult
Treatment Panel III). Third Report of the National Cholesterol Education
Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of
High Blood Cholesterol in Adults (Adult Treatment Panel III) final report.
Circulation. 2002;106(25):3143–421.
21. Emerging Risk Factors Collaboration, Erqou S, Kaptoge S, Perry PL, et al.
Lipoprotein(a) concentration and the risk of coronary heart disease, stroke,
and nonvascular mortality. JAMA. 2009;302(4):412–23.
22. Khera AV, Everett BM, Caulfield MP, et al. Lipoprotein(a) concentrations,
rosuvastatin therapy, and residual vascular risk: an analysis from the JUPITER
Trial (Justification for the Use of Statins in Prevention: an Intervention Trial
Evaluating Rosuvastatin). Circulation. 2014;129(6):635–42.
23. Kavousi M, Leening MJ, Nanchen D, et al. Comparison of application of the
ACC/AHA guidelines, Adult Treatment Panel III guidelines, and European
Saeedi and Frohlich Clinical Diabetes and Endocrinology  (2016) 2:7 Page 5 of 6
Society of Cardiology guidelines for cardiovascular disease prevention in a
European cohort. JAMA. 2014;311:1416.
24. Karmali KN, Goff Jr DC, Ning H, et al. A systematic examination of the 2013
ACC/AHA pooled cohort risk assessment tool for atherosclerotic
cardiovascular disease. J Am Coll Cardiol. 2014;64:959.
25. Sechi LA, Kronenberg F, De Carli S, et al. Association of serum lipoprotein(a)
levels and apolipoprotein(a) size polymorphism with target-organ damage
in arterial hypertension. JAMA. 1997;277:1689.
26. Goff Jr DC, Lloyd-Jones DM, Bennett G, et al. 2013 ACC/AHA guideline on
the assessment of cardiovascular risk: a report of the American College of
Cardiology/American Heart Association Task Force on Practice Guidelines.
Circulation. 2014;129:S49.
27. Davidson MH, Ballantyne CM, Jacobson TA, et al. Clinical utility of
inflammatory markers and advanced lipoprotein testing: advice from an
expert panel of lipid specialists. J Clin Lipidol. 2011;5(5):338–67.
28. Anderson TJ, Gregoire J, Hegele RA, et al. 2012 update of the Canadian
Cardiovascular Society guidelines for the diagnosis and treatment of
dyslipidemia for the prevention of cardiovascular disease in the adult. Can J
Cardiol. 2013;29(2):151–67.
29. Luc G, Bard JM, Arveiler D, et al. Lipoprotein (a) as a predictor of coronary
heart disease: the PRIME Study. Atherosclerosis. 2002;163(2):377–84.
30. Maher VM, Brown BG, Marcovina SM, et al. Effects of lowering elevated
LDL cholesterol on the cardiovascular risk of lipoprotein(a). JAMA.
1995;274(22):1771–4.
31. Saeedi R, Li M, Allard M, Frohlich J. Marked effects of extreme levels of
lipoprotein(a) on estimation of low-density lipoprotein cholesterol. Clin
Biochem. 2014;47(12):1098–9.
32. Li KM, Wilcken DE, Dudman NP. Effect of serum lipoprotein(a) on estimation
of low-density lipoprotein cholesterol by the Friedewald formula. Clin
Chem. 1994;40(4):571–3.
33. Cannon CP, Blazing MA, Giugliano RP, et al. Ezetimibe Added to Statin Therapy
after Acute Coronary Syndromes. N Engl J Med. 2015;18;372(25):2387–97.
34. Van van Wissen S, Smilde TJ, Trip MD, et al. Long term statin treatment
reduces lipoprotein(a) concentrations in heterozygous familial
hypercholesterolaemia. Heart. 2003;89:893–6.
35. Børresen AL, Berg K, Dahlén G, et al. The effect of Gemfibrozil on human
serum apolipoproteins and on serum reserve cholesterol binding capacity
(SRCBC). Artery. 1981;9:77.
36. Albers JJ, Slee A, O'Brien KD, et al. Relationship of apolipoproteins A-1 and
B, and lipoprotein(a) to cardiovascular outcomes: the AIM-HIGH trial
(Atherothrombosis Intervention in Metabolic Syndrome with Low HDL/High
Triglyceride and Impact on Global Health Outcomes). J Am Coll Cardiol.
2013;62(17):1575–9.
37. Hps Thrive Collaborative Group. HPS2-THRIVE randomized placebo-
controlled trial in 25 673 high-risk patients of ER niacin/laropiprant: trial
design, pre-specified muscle and liver outcomes, and reasons for stopping
study treatment. Eur Heart J. 2013;34(17):1279e91.
38. Li M, Saeedi R, Rabkin SW, Frohlich J. Dramatic lowering of very high Lp(a)
in response to niacin. J Clin Lipidol. 2014;8(4):448–50.
39. Lavigne PM, Karas RH. The current state of niacin in cardiovascular disease
prevention: a systematic review and meta-regression. J Am Coll Cardiol.
2013;61(4):440–6.
40. Man LC, Kelly E, Duffy D. Targeting lipoprotein (a): an evolving therapeutic
landscape. Curr Atheroscler Rep. 2015;17(5):502.
41. Koren MJ, Giugliano RP, Raal FJ, et al. Efficacy and safety of longer-term
administration of evolocumab (AMG 145) in patients with hypercholesterolemia:
52-week results from the Open-Label Study of Long-Term Evaluation against
LDL-C (OSLER) randomized trial. Circulation. 2014;129(2):234e43.
42. Juxtapid (lomitapide) capsules [package insert]. Cambridge, MA; Aegerion
Pharmaceuticals. Revised August, 2014.
43. Gotto Jr AM, Kher U, Chatterjee MS, et al. Lipids, safety parameters,
and drug concentrations after an additional 2 years of treatment with
anacetrapib in the DEFINE study. J Cardiovasc Pharmacol Ther.
2014;19(6):543–9.
44. Graham MJ, Viney N, Crooke R, et al. Antisense Inhibition of
Apolipoprotein(a) to Lower Plasma Lipoprotein(a) Levels in Humans. J Lipid
Res. 2015 Nov 4. pii: jlr.R052258. [Epub ahead of print]
45. Tsimikas S, Viney NJ, Hughes SG, et al. Antisense therapy targeting
apolipoprotein(a): a randomised, double-blind, placebo-controlled phase 1
study. Lancet. 2015;386(10002):1472–83.
46. Thompson GR. Recommendations for the use of LDL apheresis.
Atherosclerosis. 2008;198(2):247–55.
47. Leebmann J, Roeseler E, Julius U, et al. Lipoprotein apheresis in patients
with maximally tolerated lipid-lowering therapy, lipoprotein(a)-
hyperlipoproteinemia, and progressive cardiovascular disease: prospective
observational multicenter study. Circulation. 2013;128(24):2567–76.
48. Safarova MS, Ezhov MV, Afanasieva OI, et al. Effect of specific lipoprotein(a)
apheresis on coronary atherosclerosis regression assessed by quantitative
coronary angiography. Atheroscler Suppl. 2013;14(1):93e9.
49. von Dryander M, Fischer S, Passauer J, Muller G, et al. Differences in the
atherogenic risk of patients treated by lipoprotein apheresis according to
their lipid pattern. Atheroscler Suppl. 2013;14(1):39e44.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Saeedi and Frohlich Clinical Diabetes and Endocrinology  (2016) 2:7 Page 6 of 6
